CoChat

Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer’s disease

Open access
Cao, Qing, Wang, Wei, Williams, Jamal B., Yang, Fengwei, Wang, Zi-Jun, Yan, Zhen · 2020 · Science Advances

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

This study has found a novel epigenetic mechanism and a potential therapeutic strategy for AD and related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abc8096

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The level of H3K4me3 and its catalyzing enzymes SET1/MLL HMTs are significantly elevated in the PFC of postmortem tissue from patients with AD and P301S Tau mice. (A) Immunoblots and quantification analysis of H3K4me3, H3K4me, and H3K27me3 in the nuclear fraction of postmortem prefrontal cortical tissue (Brodmann’s area 10) from patients with AD versus age- and sex-matched control (ctrl) subjects. (B) Confocal images and quantification of the intensity of H3K4me3 and NeuN signals of PFC neurons immunostained with H3K4me3 and NeuN in AD and control subjects. (C) Immunoblots and quantification analysis of H3K4me3, H3K4me, and H3K27me3 in the nuclear fraction of PFC from P301S transgenic Tau mice (Tau; 5 to 6 months old) versus wild-type (WT) mice. (D) Confocal images and quantification of the intensity of H3K4me3 and NeuN signals of PFC neurons immunostained with H3K4me3 and NeuN in WT versus P301S Tau mice. (E and F) Quantitative polymerase chain reaction (qPCR) data showing the mRNA level of SET1/MLL family members KMT2A-D and SETD1A/B in PFC of postmortem tissue from patients with AD versus control subjects (E) and P301S Tau mice (5 to 6 months old) versus age-matched WT mice (F). In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, t test.
Fig. 1 The level of H3K4me3 and its catalyzing enzymes SET1/MLL HMTs are significantly elevated in the PFC of postmortem tissue from patients with AD and P301S Tau mice. (A) Immunoblots and quantification analysis of H3K4me3, H3K4me, and H3K27me3 in the nuclear fraction of postmortem prefrontal cortical tissue (Brodmann’s area 10) from patients with AD versus age- and sex-matched control (ctrl) subjects. (B) Confocal images and quantification of the intensity of H3K4me3 and NeuN signals of PFC neurons immunostained with H3K4me3 and NeuN in AD and control subjects. (C) Immunoblots and quantification analysis of H3K4me3, H3K4me, and H3K27me3 in the nuclear fraction of PFC from P301S transgenic Tau mice (Tau; 5 to 6 months old) versus wild-type (WT) mice. (D) Confocal images and quantification of the intensity of H3K4me3 and NeuN signals of PFC neurons immunostained with H3K4me3 and NeuN in WT versus P301S Tau mice. (E and F) Quantitative polymerase chain reaction (qPCR) data showing the mRNA level of SET1/MLL family members KMT2A-D and SETD1A/B in PFC of postmortem tissue from patients with AD versus control subjects (E) and P301S Tau mice (5 to 6 months old) versus age-matched WT mice (F). In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, t test.CC BY-NC · PubMed Central
Fig. 2 Administration of the H3K4-specific methyltransferase inhibitor WDR5-0103 ameliorates cognitive deficits in P301S Tau mice and 5xFAD mice. (A) Immunoblots and quantification analysis of H3K4me3 and H3K27me3 in the nuclear fraction of PFC lysates from WT versus P301S Tau mice (5 to 6 months old) treated with WDR5-0103 (2.5 mg/kg, i.p., three times) or saline control. (B and C) Bar graphs showing the time spent on exploring the familiar or novel object (B) and the discrimination index (C) in novel object recognition test (NORT) of WT versus P301S Tau mice treated with WDR5-0103 or saline. (D and E) Bar graphs showing the time spent on exploring the correct hole (T1) versus the seven incorrect holes (T2) (D) and the spatial memory index (T1/T2) (E) in Barnes maze tests of WT versus P301S Tau mice treated with WDR5-0103 or saline. (F) Representative heatmaps illustrating the time spent in different locations of the arena for Barnes maze tests during the memory phase (escape box removed). (G) Immunoblots and quantification analysis of H3K4me3 in the nuclear fraction of PFC lysates from WT versus 5xFAD mice treated with WDR5-0103 or saline. (H) Bar graph showing the discrimination index in NORT of WT versus 5xFAD mice treated with WDR5-0103 or saline. (I) Bar graphs showing the spatial memory index in the Barnes Maze test of WT versus 5xFAD mice treated with WDR5-0103 or saline. In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (A, C, E, and G to I) or t test (B and D).
Fig. 2 Administration of the H3K4-specific methyltransferase inhibitor WDR5-0103 ameliorates cognitive deficits in P301S Tau mice and 5xFAD mice. (A) Immunoblots and quantification analysis of H3K4me3 and H3K27me3 in the nuclear fraction of PFC lysates from WT versus P301S Tau mice (5 to 6 months old) treated with WDR5-0103 (2.5 mg/kg, i.p., three times) or saline control. (B and C) Bar graphs showing the time spent on exploring the familiar or novel object (B) and the discrimination index (C) in novel object recognition test (NORT) of WT versus P301S Tau mice treated with WDR5-0103 or saline. (D and E) Bar graphs showing the time spent on exploring the correct hole (T1) versus the seven incorrect holes (T2) (D) and the spatial memory index (T1/T2) (E) in Barnes maze tests of WT versus P301S Tau mice treated with WDR5-0103 or saline. (F) Representative heatmaps illustrating the time spent in different locations of the arena for Barnes maze tests during the memory phase (escape box removed). (G) Immunoblots and quantification analysis of H3K4me3 in the nuclear fraction of PFC lysates from WT versus 5xFAD mice treated with WDR5-0103 or saline. (H) Bar graph showing the discrimination index in NORT of WT versus 5xFAD mice treated with WDR5-0103 or saline. (I) Bar graphs showing the spatial memory index in the Barnes Maze test of WT versus 5xFAD mice treated with WDR5-0103 or saline. In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (A, C, E, and G to I) or t test (B and D).CC BY-NC · PubMed Central
Fig. 3 WDR5-0103 restores glutamatergic transmission and synaptic glutamate receptor expression in P301S Tau mice. (A and B) Input-output curves of AMPAR-EPSC (A) and NMDAR-EPSC (B) in response to a series of stimulation intensities in PFC pyramidal neurons from WT mice or P301S Tau mice (5 to 6 months old) treated with WDR5-0103 (2.5 mg/kg, i.p., three times) or saline control. Inset: Representative EPSC traces at different stimuli. (C) Bar graphs showing sEPSC amplitude and frequency in WT or P301S Tau mice treated with WDR5-0103 or saline. Inset: sEPSC traces. (D and E) Immunoblots and quantification of GluR1, GluR2, NR1, NR2A, and NR2B expression in the synaptic fraction of PFC from postmortem tissue of patients with AD versus control subjects (D) and WT mice versus P301S Tau mice treated with WDR5-0103 or saline (E). In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (A to C and E) or t test (D).
Fig. 3 WDR5-0103 restores glutamatergic transmission and synaptic glutamate receptor expression in P301S Tau mice. (A and B) Input-output curves of AMPAR-EPSC (A) and NMDAR-EPSC (B) in response to a series of stimulation intensities in PFC pyramidal neurons from WT mice or P301S Tau mice (5 to 6 months old) treated with WDR5-0103 (2.5 mg/kg, i.p., three times) or saline control. Inset: Representative EPSC traces at different stimuli. (C) Bar graphs showing sEPSC amplitude and frequency in WT or P301S Tau mice treated with WDR5-0103 or saline. Inset: sEPSC traces. (D and E) Immunoblots and quantification of GluR1, GluR2, NR1, NR2A, and NR2B expression in the synaptic fraction of PFC from postmortem tissue of patients with AD versus control subjects (D) and WT mice versus P301S Tau mice treated with WDR5-0103 or saline (E). In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (A to C and E) or t test (D).CC BY-NC · PubMed Central
Fig. 4 WDR5-0103 treatment induces genome-wide rescue of gene expression in PFC of Tau AD model. (A and D) Heatmaps representing expression (row z-score) of genes that were up-regulated (A) or down-regulated (D) in saline-treated P301S Tau samples (Tau), compared to WT samples (WT), and reversed in WDR5-0103 (2.5 mg/kg, i.p., three times)–treated P301S Tau samples (WDR5). (B and E) Functional protein classification analysis of the up-regulated and WDR5-reversed genes (B) or the down-regulated and WDR5-reversed genes (E). (C and F) GO Biological Process analysis of the up-regulated and WDR5-reversed genes (C) or the down-regulated and WDR5-reversed genes (F).
Fig. 4 WDR5-0103 treatment induces genome-wide rescue of gene expression in PFC of Tau AD model. (A and D) Heatmaps representing expression (row z-score) of genes that were up-regulated (A) or down-regulated (D) in saline-treated P301S Tau samples (Tau), compared to WT samples (WT), and reversed in WDR5-0103 (2.5 mg/kg, i.p., three times)–treated P301S Tau samples (WDR5). (B and E) Functional protein classification analysis of the up-regulated and WDR5-reversed genes (B) or the down-regulated and WDR5-reversed genes (E). (C and F) GO Biological Process analysis of the up-regulated and WDR5-reversed genes (C) or the down-regulated and WDR5-reversed genes (F).CC BY-NC · PubMed Central
Fig. 5 ChIPseq reveals up-regulated genes with the increased H3K4me3 occupancy at their promoters in P301S Tau mice. (A) Profile plot showing H3K4me3 TSS occupancy of all genes in PFC from WT versus Tau mice. (B) Functional classification of the overlapping genes that show up-regulated transcription in RNA-seq (Tau versus WT) and increased H3K4me3 occupancy in ChIPseq (Tau versus WT). (C) Circos plots showing genes in each of the 19 chromosomes with up-regulated transcription in RNA-seq (Tau versus WT) and increased H3K4me3 occupancy in ChIPseq (Tau versus WT). Dots scattered at the most outside of circles are genes with higher statistical significances. Top-ranking genes in each chromosome are labeled in the center. Sgk1 is the gene on both top lists. (D) ChIPseq data showing the landscape of H3K4me3 peaks around TSS of Sgk1 gene in PFC from WT and P301S Tau mice. The increased H3K4me3 binding sites are highlighted with dotted lines based on differential peak calling analysis of ChIPseq data.
Fig. 5 ChIPseq reveals up-regulated genes with the increased H3K4me3 occupancy at their promoters in P301S Tau mice. (A) Profile plot showing H3K4me3 TSS occupancy of all genes in PFC from WT versus Tau mice. (B) Functional classification of the overlapping genes that show up-regulated transcription in RNA-seq (Tau versus WT) and increased H3K4me3 occupancy in ChIPseq (Tau versus WT). (C) Circos plots showing genes in each of the 19 chromosomes with up-regulated transcription in RNA-seq (Tau versus WT) and increased H3K4me3 occupancy in ChIPseq (Tau versus WT). Dots scattered at the most outside of circles are genes with higher statistical significances. Top-ranking genes in each chromosome are labeled in the center. Sgk1 is the gene on both top lists. (D) ChIPseq data showing the landscape of H3K4me3 peaks around TSS of Sgk1 gene in PFC from WT and P301S Tau mice. The increased H3K4me3 binding sites are highlighted with dotted lines based on differential peak calling analysis of ChIPseq data.CC BY-NC · PubMed Central
Fig. 6 Inhibition of the up-regulated Sgk1 in P301S Tau mice reduces hyperphosphorylated tau and restores AMPAR function and synaptic glutamate receptor expression. (A) qPCR data showing sgk1 mRNA in PFC from WT versus P301S Tau mice, postmortem control human subjects versus patients with AD or WT versus 5xFAD mice. (B) Immunoblots and quantification of S202/T205p-tau (detected by AT8 antibody) or S214p-tau in PFC lysates from postmortem control subjects versus patients with AD. (C) Immunoblots and quantification of S202/T205p-tau or S214p-tau in PFC lysates from WT versus P301S Tau mice (5 to 6 months old) treated with the Sgk1 inhibitor GSK650394 (Sgk1i; 1 mg/kg, i.p., three time) or saline. (D) Images of immunostaining of S202/T205p-tau in PFC slices from P301S Tau mice treated with Sgk1i or saline. Scale bars, 20 μm. (E) Input-output curves of AMPAR-EPSC in PFC pyramidal neurons from WT or P301S Tau mice injected with Sgk1i or saline. Inset: Representative EPSC traces. (F) Bar graphs showing sEPSC amplitude and frequency in PFC pyramidal neurons from WT or P301S Tau mice injected with Sgk1i or saline. Inset: sEPSC traces. (G and H) Quantification and representative immunoblots of GluR1, GluR2, NR1, NR2A, and NR2B expression in the synaptic fraction of PFC from WT or P301S Tau mice injected with Sgk1i or saline. In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (C and E to G) or t test (A and B).
Fig. 6 Inhibition of the up-regulated Sgk1 in P301S Tau mice reduces hyperphosphorylated tau and restores AMPAR function and synaptic glutamate receptor expression. (A) qPCR data showing sgk1 mRNA in PFC from WT versus P301S Tau mice, postmortem control human subjects versus patients with AD or WT versus 5xFAD mice. (B) Immunoblots and quantification of S202/T205p-tau (detected by AT8 antibody) or S214p-tau in PFC lysates from postmortem control subjects versus patients with AD. (C) Immunoblots and quantification of S202/T205p-tau or S214p-tau in PFC lysates from WT versus P301S Tau mice (5 to 6 months old) treated with the Sgk1 inhibitor GSK650394 (Sgk1i; 1 mg/kg, i.p., three time) or saline. (D) Images of immunostaining of S202/T205p-tau in PFC slices from P301S Tau mice treated with Sgk1i or saline. Scale bars, 20 μm. (E) Input-output curves of AMPAR-EPSC in PFC pyramidal neurons from WT or P301S Tau mice injected with Sgk1i or saline. Inset: Representative EPSC traces. (F) Bar graphs showing sEPSC amplitude and frequency in PFC pyramidal neurons from WT or P301S Tau mice injected with Sgk1i or saline. Inset: sEPSC traces. (G and H) Quantification and representative immunoblots of GluR1, GluR2, NR1, NR2A, and NR2B expression in the synaptic fraction of PFC from WT or P301S Tau mice injected with Sgk1i or saline. In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA (C and E to G) or t test (A and B).CC BY-NC · PubMed Central
Fig. 7 Inhibition of the up-regulated Sgk1 in P301S Tau mice alleviates cognitive deficits. (A and B) Bar graphs showing the time spent on exploring the correct hole (T1) and the seven incorrect holes (T2) (A) and the spatial memory index (T1/T2) (B) in Barnes maze tests of WT versus P301S Tau mice treated with the Sgk1 inhibitor GSK650394 (Sgk1i; 1 mg/kg, i.p., three times) or saline control. (C) Plot of spatial memory index in P301S Tau mice before and after the treatment with Sgk1i or saline at different time points. (D and E) Bar graphs showing the time spent on exploring the familiar and novel objects (D) and the discrimination index (E) in NORT of WT versus P301S Tau mice treated with Sgk1i or saline control. (F) Plot of spatial memory index in P301S Tau mice before and after the treatment with Sgk1i or saline at different time points. In all figures, *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA (B and E) or t test (A and D) or **P < 0.01, saline vs. Sgk1i; ##P < 0.01, pre- vs. post-injection, rmANOVA (C and F).
Fig. 7 Inhibition of the up-regulated Sgk1 in P301S Tau mice alleviates cognitive deficits. (A and B) Bar graphs showing the time spent on exploring the correct hole (T1) and the seven incorrect holes (T2) (A) and the spatial memory index (T1/T2) (B) in Barnes maze tests of WT versus P301S Tau mice treated with the Sgk1 inhibitor GSK650394 (Sgk1i; 1 mg/kg, i.p., three times) or saline control. (C) Plot of spatial memory index in P301S Tau mice before and after the treatment with Sgk1i or saline at different time points. (D and E) Bar graphs showing the time spent on exploring the familiar and novel objects (D) and the discrimination index (E) in NORT of WT versus P301S Tau mice treated with Sgk1i or saline control. (F) Plot of spatial memory index in P301S Tau mice before and after the treatment with Sgk1i or saline at different time points. In all figures, *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA (B and E) or t test (A and D) or **P < 0.01, saline vs. Sgk1i; ##P < 0.01, pre- vs. post-injection, rmANOVA (C and F).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 110

Metadata

Authors
Cao, Q., Wang, W., Williams, J. B., Yang, F., Wang, Z.-J., & Yan, Z.
Affiliations
  • University at Buffalo, State University of New York (US)
  • Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
Corresponding author
Yan, Zhen
Venue
Science Advances
Published
2020-12-11
Volume
6
Issue
50
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3111509032
Cited by
108
References
73
Citations by year
2026: 19 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 17 · 2021: 8
FWCI
6.92
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (AG064656, AG056060, AG067597)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
histone H3 lysine 4 trimethylation, Alzheimer's disease, SGK1, SGK1 inhibitor, tau hyperphosphorylation, prefrontal cortex, memory impairment, epigenetic therapy, cognitive impairment
MeSH terms
Alzheimer Disease, Animals, Cognition, Disease Models, Animal, Histones, Humans, tau Proteins, Epigenesis, Genetic, Intracellular Signaling Peptides and Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.